All PNV need are capable management and a strategic, capable and aligned board. The current top structure is an impediment to execution, thats plain to see. David has the board stacked with yes-men, so until he goes, its unlikely this ever gets resolved. They need an independent board, pure and simple.
Agree that BTM has the potential to have a complete new silo, but if they cant execute on a business that's 'already grown to fast, and has a lot of governance and management issues' - that's a finding from the recent legal firms looking in, then what chance do they have realistically have in executing their business model on an even bigger market. Given studies in larger populations take many years, while it will be 'easier' given BTM is already approved, it will be 5 years plus before any revenue comes from this market.
They are drawing down on cash reserves fast, so anticipate yet another capital raise, which David Williams and his firm will get paid handsomely for. Yet another conflict of interest that only gets resolved on him being departed.
I love the potential of the PNV's Novosorb product, its easy to put a large TAM into play. But execution is everything in business, and Patent protection only lasts so long, as does investor patience. I sold out on the recent spike, but will watch closely to how this all unfolds.
PNV Price at posting:
$1.49 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)